CD55/DAF Polyclonal Antibody

$Formalin-fixed and paraffin embedded human lung carcinoma labeled with Anti-CD55\/DAF Polyclonal Antibody, Unconjugated (bs-1552R) at 1:200 followed by conjugation to the secondary antibody and DAB staining.$

Formalin-fixed and paraffin embedded human lung carcinoma labeled with Anti-CD55\/DAF Polyclonal Antibody, Unconjugated (bs-1552R) at 1:200 followed by conjugation to the secondary antibody and DAB staining.

Applications

ELISA
FCM
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)

Reactivity

Human

Overview
Catalog #	bs-1552R
Product Name	CD55/DAF Polyclonal Antibody
Applications	ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human CD55
Immunogen Range	301-381/381
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	1604
Swiss Prot	P08174
Subcellular location	Secreted, Cell membrane
Synonyms	CR; TC; DAF; CROM; Complement decay-accelerating factor; CD55
Background	This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.
Application Dilution
ELISA	1:500-1000
FCM	1:20-100
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200